Author/Creator: Linke, R - British Library Electronic Legal Deposit Catalogue-Journal Issues and Articles Search Results

Author/Creator Linke, R

1. 480PSafety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050. (24th November 2019)

Authors:: Mok, T S K; Cheng, Y; Zhou, X; Lee, K H; Nakagawa, K; Niho, S; Rosell, R; Linke, R; Wong, C H; Tang, Y; Singh, M; Wilner, K D; Wu, Y-L
Journal:: Annals of oncology
Issue:: Volume 30(2019)Supplement 9
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

2. 487PPatient selection for targeting integrin with abituzumab in patients with metastatic colorectal cancer (mCRC): A retrospective analysis of the randomized phase I/II Poseidon study. (23rd October 2018)

Authors:: Laeufle, R; Arnold, D; Kopetz, S; Straub, J; Bruns, R; Massimini, G; Debenedetto, R; Linke, R; Elez Fernandez, E; Tabernero, J
Journal:: Annals of oncology
Issue:: Volume 29(2018)Supplement 8
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

3. 863OAxitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results. (23rd October 2018)

Authors:: Gross-Goupil, M; Kwon, T G; Eto, M; Ye, D; Miyake, H; Seo, S I; Byun, S S; Lee, J L; Master, V; Jin, J; Debenedetto, R; Linke, R; Casey, M; Rosbrook, B; Lechuga Frean, M J; Valota, O; Grande, E; Quinn, D I
Journal:: Annals of oncology
Issue:: Volume 29(2018)Supplement 8
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

4. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. (20th October 2018)

Authors:: Gross-Goupil, M; Kwon, T G; Eto, M; Ye, D; Miyake, H; Seo, S I; Byun, S -S; Lee, J L; Master, V; Jin, J; DeBenedetto, R; Linke, R; Casey, M; Rosbrook, B; Lechuga, M; Valota, O; Grande, E; Quinn, D I
Journal:: Annals of oncology
Issue:: Volume 29:Number 12(2018)
Page Start:: 2371
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

5. Dopaminergic deficit in amyotrophic lateral sclerosis assessed with [I-123] IPT single photon emission computed tomography. Issue 2 (1st August 1998)

Authors:: Borasio, G D; Linke, R; Schwarz, J; Schlamp, V; Abel, A; Mozley, P D; Tatsch, K
Journal:: Journal of neurology, neurosurgery and psychiatry
Issue:: Volume 65:Issue 2(1998)
Page Start:: 263
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

6. LBA19Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations. (24th November 2019)

Authors:: Mok, T S K; Cheng, Y; Zhou, X; Lee, K H; Nakagawa, K; Niho, S; Linke, R; Rosell, R; Corral, J; Migliorino, M R; Pluzanski, A; Noonan, K; Tang, Y; Wilner, K D; Wu, Y-L
Journal:: Annals of oncology
Issue:: Volume 30(2019)Supplement 9
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

7. P683Intramyocardial inflammation correlates with poor prognosis in patients with cardiac AL amyloidosis. (28th August 2018)

Authors:: Escher, F; Siegismuns, C S; Lassner, D; Gross, U; Linke, R; Schultheiss, H P
Journal:: European heart journal
Issue:: Volume 39(2018)Supplement 1
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗